AUNG BAJAJ M.D NPI 1598177255

NPI Information

  • NPI: 1598177255
  • Provider Name: AUNG BAJAJ, M.D
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 603 N WILMOT RD STE 151
    TUCSON, AZ
    ZIP 85711
  • Phone: (520) 420-2560

Map and Directions

Get Directions

NPI Details

Aung Bajaj, M.D is a hematology and oncology internal medicine in Tucson, AZ with 12 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Aung Bajaj, M.D NPI is 1598177255. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

603 N WILMOT RD STE 151
TUCSON, AZ
ZIP 85711-701
Phone: (520) 420-2560
Fax: (520) 420-2562

The NPI 1598177255 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection, fulvestrant, 25 mg (HCPCS:J9395)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, etoposide, 10 mg (HCPCS:J9181)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • Unclassified drugs (HCPCS:J3490)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)

The enumeration date for this NPI number is 5/28/2014 and was last updated on 5/12/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology53908ARIZONAYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.